Liminatus Pharma, Inc. completed its acquisition of InnocsAI LLC on 2026-07-02, according to the Form 8-K Liminatus Pharma, Inc. filed with the SEC on 2026-07-06. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Liminatus Pharma, Inc. |
|---|---|
| Acquired | InnocsAI LLC |
| Completed | 2026-07-02 |
| Reported by | Liminatus Pharma, Inc. (LIMN), the buyer |
| Filing | Form 8-K, filed 2026-07-06 |
Want the whole picture on Liminatus Pharma, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Liminatus Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Liminatus Pharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On July 2, 2026, the Company, InnocsAI, and Merger Sub consummated the Merger described in Item 1.01 above, pursuant to which the Company acquired InnocsAI.
More from the filing
Entry into a Material Definitive Agreement.
Amended and Restated Merger Agreement On June 29, 2026, Liminatus Pharma, Inc. (the "Company"), InnocsAI LLC, a Delaware limited liability company ("InnocsAI"), and NamChul Jung, an individual, as the representative of the members of InnocsAI, entered into an Amended and Restated Merger Agreement (the "Amended and Restated Merger Agreement"), which amends and restates in its entirety the Merger Agreement, dated as of May 17, 1026, by and among the Company, InnocsAI and Mr. Jung (the "Original Merger Agreement").
Pursuant to the Amended and Restated Merger Agreement, the Company and InnocsAI agreed to revise the structure of the previously announced transaction to allow closing prior to obtaining stockholder approval and to provide that the 1,600,000,000 shares of the Company's common stock representing merger consideration shares to be paid to the members of InnocsAI in the Merger (as defined below) will be paid in a combination of shares of the Company's common stock and newly designated non-voting convertible preferred stock.
Quoted from Liminatus Pharma, Inc.'s Form 8-K.
This is the only completed acquisition Liminatus Pharma, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Liminatus Pharma, Inc.Look up Liminatus Pharma, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.